MAGE A3 TCR / Gilead, National Cancer Institute - LARVOL DELTA

T Cell Receptor Immunotherapy Targeting MAGE-A3 for Patients With Metastatic Cancer Who Are HLA-DP0401 Positive (clinicaltrials.gov) - P1/2; N=107; Recruiting; Sponsor: National Cancer Institute (NCI); Trial primary completion date: Dec 2017 ➔ Dec 2023

Clinical • Trial primary completion date • Breast Cancer • Cervical Cancer • Genito-urinary Cancer • Kidney Cancer • Melanoma • Renal Cell Carcinoma • Solid Tumor • Urothelial Cancer • GAPDH

T Cell Receptor Immunotherapy Targeting MAGE-A3 for Patients With Metastatic Cancer Who Are HLA-DP0401 Positive (clinicaltrials.gov) - P1/2; N=107; Recruiting; Sponsor: National Cancer Institute (NCI); Phase classification: P2 ➔ P1/2

Clinical • Phase classification • Breast Cancer • Cervical Cancer • Gynecologic Cancers • Kidney Cancer • Melanoma • Renal Cell Carcinoma • GAPDH

T Cell Receptor Immunotherapy Targeting MAGE-A3 for Patients With Metastatic Cancer Who Are HLA-DP0401 Positive (clinicaltrials.gov) - P1/2; N=107; Recruiting; Sponsor: National Cancer Institute (NCI); Suspended ➔ Recruiting; N=18 ➔ 107

Clinical • Enrollment change • Enrollment open • Breast Cancer • Cervical Cancer • Genito-urinary Cancer • Kidney Cancer • Melanoma • Oncology • Renal Cell Carcinoma • Solid Tumor • Urothelial Cancer • GAPDH

T Cell Receptor Immunotherapy Targeting MAGE-A3 for Patients With Metastatic Cancer Who Are HLA-DP0401 Positive (clinicaltrials.gov) - P1/2; N=107; Recruiting; Sponsor: National Cancer Institute (NCI)

Clinical • New P1/2 trial • Breast Cancer • Cervical Cancer • Genito-urinary Cancer • Kidney Cancer • Melanoma • Oncology • Renal Cell Carcinoma • Solid Tumor • Urothelial Cancer • GAPDH

T Cell Receptor Immunotherapy Targeting MAGE-A3 for Patients With Metastatic Cancer Who Are HLA-DP0401 Positive (clinicaltrials.gov) - P1/2; N=21; Completed; Sponsor: National Cancer Institute (NCI); Active, not recruiting ➔ Completed

Trial completion • Breast Cancer • Cervical Cancer • Genito-urinary Cancer • Kidney Cancer • Melanoma • Oncology • Renal Cell Carcinoma • Solid Tumor • Urothelial Cancer • GAPDH

T Cell Receptor Immunotherapy Targeting MAGE-A3 for Patients With Metastatic Cancer Who Are HLA-DP0401 Positive (clinicaltrials.gov) - P1/2; N=21; Active, not recruiting; Sponsor: National Cancer Institute (NCI); Recruiting ➔ Active, not recruiting; N=107 ➔ 21

Clinical • Enrollment change • Enrollment closed • Breast Cancer • Cervical Cancer • Genito-urinary Cancer • Gynecologic Cancers • Kidney Cancer • Melanoma • Oncology • Renal Cell Carcinoma • Solid Tumor • Urothelial Cancer • GAPDH

T Cell Receptor Immunotherapy Targeting MAGE-A3 for Patients With Metastatic Cancer Who Are HLA-DP0401 Positive (clinicaltrials.gov) - P1/2; N=16; Suspended; Sponsor: National Cancer Institute (NCI); N=107 ➔ 16; Recruiting ➔ Suspended

Clinical • Enrollment change • Trial suspension • Breast Cancer • Cervical Cancer • Genito-urinary Cancer • Kidney Cancer • Melanoma • Oncology • Renal Cell Carcinoma • Solid Tumor • Urothelial Cancer • GAPDH

T Cell Receptor Immunotherapy Targeting MAGE-A3 for Patients With Metastatic Cancer Who Are HLA-DP0401 Positive (clinicaltrials.gov) - P1/2; N=107; Recruiting; Sponsor: National Cancer Institute (NCI); Trial primary completion date: Sep 2015 ➔ Jan 2017

Clinical • Trial primary completion date • Breast Cancer • Cervical Cancer • Genito-urinary Cancer • Kidney Cancer • Melanoma • Oncology • Renal Cell Carcinoma • Solid Tumor • Urothelial Cancer • GAPDH

T Cell Receptor Immunotherapy Targeting MAGE-A3 for Patients With Metastatic Cancer Who Are HLA-DP0401 Positive (clinicaltrials.gov) - P1/2; N=18; Suspended; Sponsor: National Cancer Institute (NCI); Trial primary completion date: Dec 2016 ➔ Dec 2017

Clinical • Trial primary completion date • Breast Cancer • Cervical Cancer • Genito-urinary Cancer • Kidney Cancer • Melanoma • Oncology • Renal Cell Carcinoma • Solid Tumor • Urothelial Cancer • GAPDH

T Cell Receptor Immunotherapy Targeting MAGE-A3 for Patients With Metastatic Cancer Who Are HLA-DP0401 Positive (clinicaltrials.gov) - P2; N=107; Recruiting; Sponsor: National Cancer Institute (NCI); Phase classification: P1/2 ➔ P2

Clinical • Phase classification • Breast Cancer • Cervical Cancer • Gynecologic Cancers • Kidney Cancer • Melanoma • Renal Cell Carcinoma • GAPDH

T Cell Receptor Immunotherapy Targeting MAGE-A3 for Patients With Metastatic Cancer Who Are HLA-A*01 Positive (clinicaltrials.gov) - P1/2; N=102; Recruiting; Sponsor: National Cancer Institute (NCI); Trial completion date: Dec 2024 ➔ Jan 2019; Trial primary completion date: Dec 2023 ➔ Jan 2019

Trial completion date • Trial primary completion date • Biosimilar • Bladder Cancer • Breast Cancer • Genito-urinary Cancer • Gynecologic Cancers • Hematological Malignancies • Melanoma • Oncology • Renal Cell Carcinoma • Solid Tumor